Are Myelodysplastic Syndromes Underdiagnosed in Poland? A Report by the Polish Adult Leukaemia Group
PBN-AR
Instytucja
Instytut Badań Edukacyjnych
Źródłowe zdarzenia ewaluacyjne
Are Myelodysplastic Syndromes Underdiagnosed in Poland? A Report by the Polish Adult Leukaemia Group (zgłoszony przez Instytut Badań Edukacyjnych) Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group (zgłoszony przez Instytut Badań Edukacyjnych) Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group (zgłoszony przez Wydział Lekarski) Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group. (zgłoszony przez Wydział Lekarsko - Biotechnologiczny i Medycyny Laboratoryjnej) Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group. (zgłoszony przez Wydział Lekarski z Oddziałem Stomatologii i Oddziałem Nauczania w Języku Angielskim) Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group (zgłoszony przez Instytut Hematologii i Transfuzjologii) Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group (zgłoszony przez I Wydział Lekarski) Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group (zgłoszony przez I Wydział Lekarski) Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group. (zgłoszony przez Wojskowy Instytut Medyczny) Are myelodysplastic syndromes underdiagnosed in Poland? : a report by the Polish Adult Leukaemia Group (zgłoszony przez Wydział Lekarski) Are myelodysplastic syndromes underdiagnosed in Poland? A report by the Polish Adult Leukaemia Group. (zgłoszony przez Wydział Lekarsko - Dentystyczny)
Informacje podstawowe
Główny język publikacji
angielski
Czasopismo
European Journal of Haematology (25pkt w roku publikacji)
ISSN
0902-4441
EISSN
1600-0609
Wydawca
WILEY-BLACKWELL
DOI
URL
Rok publikacji
2017
Numer zeszytu
2
Strony od-do
154-159
Numer tomu
98
Identyfikator DOI
Liczba arkuszy
0,5
Słowa kluczowe
angielski
myelodysplastic syndrome
incidence
prevalence
Open access
Tryb otwartego dostępu
Otwarte repozytorium
Wersja tekstu w otwartym dostępie
Wersja opublikowana
Licencja otwartego dostępu
Inna
Czas opublikowania w otwartym dostępie
Przed publikacją
Streszczenia
Język
angielski
Treść
Objectives The epidemiology of myelodysplastic syndromes (MDS) differs among countries. Here, we present the first epidemiological indices determined for Poland. Methods Twenty-one haematological centres participated in the study. Patients diagnosed with MDS and acute myeloid leukaemia (AML) with 20–29% blasts were enrolled. Data collection was conducted for strictly predefined period. Results The overall crude incidence rate for all MDS subtypes was 1.95 (95% CI, 1.81–2.09) per 100 000 person-years: 2.46 (95% CI, 2.24–2.69) for males and 1.47 (95% CI, 1.31–1.65) for females; after excluding AML cases, the indices were as follows: 2.35 (95% CI, 2.08–2.66) for males and 1.27 (95% CI, 1.08–1.5) for females. Prevalence rate was 6.2 per 100 000 persons (95% CI, 5.96–6.45), that is 6.86 (95% CI, 6.49–7.24) for males and 5.58 (95% CI, 5.26–5.92) for females. Both incidence and prevalence increased with increasing age. The most frequently diagnosed MDS subtype was refractory cytopenia with multilineage dysplasia (RCMD), responsible for 30.3% of all newly diagnosed MDSs. Conclusions RCMD is the most frequent MDS subtype in Poland. Incidence and prevalence indices are lower than those reported for other populations, which probably results from inadequate diagnosis of potential cases of this disease. Myelodysplastic syndromes (MDSs) constitute a heterogeneous group of clonal myeloid disorders characterised by an ineffective haematopoiesis, peripheral blood cytopenias and predisposition to transformation into acute myeloid leukaemia (AML). MDS subtypes differ in terms of clinical performance and prognosis. The MDS classification has been evolving in the last decades, with FAB classification being substituted and supplemented by the WHO classification. At present, MDS are classified as malignancies, although it was quite debatable for several years. It is quite important because earlier, without classification as malignant disorders, MDSs were not reported to the cancer registries. As a result of all the above-mentioned phenomena, knowledge on MDS incidence and prevalence is limited [1]. Furthermore, it must be emphasised that different MDS registries yield a wide range of results concerning epidemiological indices in MDS [2]. With certainty, differences exist among populations, or even between different geographical regions of the same population [3]. Therefore, the results obtained in different population studies should not be extrapolated to other cohorts. Although no increase in incidence was observed in the Düsseldorf registry [4, 5], such a phenomenon could be expected due to both availability of chemo- and radiotherapy potentially leading to therapy-related MDS (t-MDS), and due to ageing of the global population. Taking into account all the above-mentioned facts, it is quite understandable that there is a need for national epidemiological studies enabling determination of MDS incidence and prevalence. In Poland, epidemiological studies on MDS are only ongoing; thus, no data concerning MDS incidence and prevalence are available. Therefore, the aim of this study was to assess the incidence and prevalence of MDS, especially in Polish population.
Inne
System-identifier
PX-5a32548fd5de3d769307232e
CrossrefMetadata from Crossref logo
Cytowania
Liczba prac cytujących tę pracę
Brak danych
Referencje
Liczba prac cytowanych przez tę pracę
Brak danych